Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible - Wikidata - awgldk - TriplyDB

Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible

Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible

http://www.wikidata.org/entity/Q34574472

about

Therapeutic targeting of cancers with loss of PTEN function.Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome Prognostic significance of miR-205 in endometrial cancer.Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.Bridging the gap: moving predictive and prognostic assays from research to clinical use Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.Long non-coding RNA derived miR-205-5p modulates human endometrial cancer by targeting PTEN.Measuring the biological effect of presurgical metformin treatment in endometrial cancer.Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.High-grade endometrial carcinomas - strategies for typing.Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.The diagnostic role of PTEN and ARID1A in serous effusions.Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases.Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma.Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab.Luteinizing Hormone/Human Chorionic Gonadotropin Receptor Immunohistochemical Score Associated with Poor Prognosis in Endometrial Cancer Patients.

P2860

Q27852764-5765EB25-A583-470E-896D-2D9B776FDDCB Q28085485-E1EEF0FB-D2A9-4A67-91BA-9FD72CBF89D8 Q33996492-80730E22-450F-490B-9E00-C2A2498D639D Q34238901-76EF3BC5-FFA3-433A-A93A-3C48927291B3 Q35151381-33AED97D-4779-4112-A4EC-FCD2EDA7FB15 Q35838577-A111DF22-21FD-49B3-B9CB-8494F4D65A04 Q35926060-164211AD-90DF-4A1E-92EC-A0E16A886FAA Q36096004-2D027439-18B2-42EB-88D1-2045B814205C Q36420288-6B9E6819-AAE6-4372-BD34-7778C96E358D Q36547907-4CF1EF9A-45D6-4F8A-865F-F0E06EC9B2E8 Q36841899-F3B1AEF7-C20B-4789-AA31-60B7F88C7675 Q37038863-78FFE97A-94D8-4828-B63E-722AC0386A3D Q38042638-AAC3599C-E454-41CB-9471-1B6B1E7BD116 Q38067439-052F19D8-48E3-4109-B500-883417204DD9 Q46053202-0E2E4C8A-7DA3-452F-A132-0E0115DC22E2 Q47369086-0A0B5B11-0568-4646-A800-A5D7F585A712 Q47908752-CEB0232C-2D9D-4227-8389-81B9521B9290 Q48221255-0550A885-3906-4882-9985-937420421A2D Q49158742-1D41583D-4EEC-440C-8AA9-DC702A302F75 Q52318912-65D7814D-4B3D-455C-94CB-647019201B13 Q54302143-1403A697-3284-4610-B04D-6771380039D2 Q54350258-26CA5494-EE67-4964-9D80-6C30BB03BBAA Q55093007-EE87E64A-5623-4476-AF30-2715A5EBC67A

P2860

Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible

http://www.wikidata.org/entity/Q34574472

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@ast

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@en

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@nl

type

label

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@ast

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@en

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@nl

prefLabel

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@ast

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@en

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@nl

P1433

Q34574472-50E7A32A-A419-4147-9BEF-3D8E9EFB6483

P1476

Q34574472-A418CA15-C54A-48B8-91A3-C6BB3D7835D6

P2093

Q34574472-0CDC25D8-696E-4688-9A28-F7291B0CD240

Q34574472-601395CF-8FE6-4D13-B155-BED1EEAC4E46

Q34574472-74E2FB80-0277-48B0-9609-1F117F7D8B16

Q34574472-977CDD54-BDC4-4420-BAF1-E7A91645D9D9

Q34574472-E653F615-53FD-4C01-865A-2AF75F12D238

Q34574472-F11F19C3-B970-45C9-81B8-8079F5A3457B

P2860

Q34574472-122360D2-C1B3-4038-B616-C800D9AF1050

Q34574472-1E52D30C-2B36-4A2F-8647-C667C1E82F1C

Q34574472-2D884FE2-2E2B-4C91-B6DD-7A9D24D6768D

Q34574472-310D76F7-963B-43B3-A18E-81CFC7F3D1EA

Q34574472-38C00E39-6639-4A15-8DD3-9326C8446E03

Q34574472-49584A4C-9AF1-4464-A1E9-C6E53156A600

Q34574472-50A4D7B7-985F-476B-8352-A6DDFE345C3F

Q34574472-54C081A0-F060-4E23-83C8-EB551CA60B69

Q34574472-6A710BD0-8786-4F8D-988E-D0D9F7241B20

Q34574472-6E40F70D-9AFC-4E3E-982D-7AE05D2E11DD

P304

Q34574472-4EF909A7-9BD0-48C0-9D0F-861841B923F6

P31

Q34574472-7BFCEEE8-A725-4202-B744-6FED087780DF

P356

Q34574472-EC63E96C-0CC6-4C11-801F-D259B8CF3626

P433

Q34574472-DA38E621-8B56-42AD-BC35-F5BC1464810E

P478

Q34574472-1A14A48C-8AF7-4DA4-9666-F6FFA56E50DF

P577

Q34574472-D3B08B1E-2C32-4BCE-9E0A-7691539DDFC3

P698

Q34574472-FED2CDC5-A527-4D20-8C92-61FF55A0132B

P921

Q34574472-5588C0A2-DA72-44E4-B39A-65D27549815A

Q34574472-91164CC9-C408-4E8E-BB58-46700BAE6930

P932

Q34574472-118520F1-8491-43A8-920D-5526AEC3FCC5

P356

PGP.0B013E3182230D00

P1433

International Journal of Gynecological Pathology

P1476

Pathologic scoring of PTEN imm ...... rcinoma is highly reproducible

@en

P2093

Bojana Djordjevic

http://www.w3.org/2001/XMLSchema#string

Diana L Urbauer

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Karuna Garg

http://www.w3.org/2001/XMLSchema#string

Robert A Soslow

http://www.w3.org/2001/XMLSchema#string

Russell R Broaddus

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Two pathogenetic types of endometrial carcinoma.

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy.

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

PI(3)king apart PTEN's role in cancer.

P304

48-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PGP.0B013E3182230D00

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22123723

http://www.w3.org/2001/XMLSchema#string

P921

reproducibility

immunohistochemistry

P932

4244710

http://www.w3.org/2001/XMLSchema#string